Uric acid is independent cardiovascular risk factor, as manifested by increased carotid intima-media thickness in

Suad Hannawi1, Issa AlSalmi2, Ingrid Moller3

  • 1Ministry of Health and Prevention, P.O.Box 65522, Dubai, United Arab Emirates. suad1@ausdoctors.net.

Insights

Serum uric acid (SUA) is a cardiovascular risk factor in rheumatoid arthritis (RA) patients, indicated by increased carotid intima-media thickness (cIMT). This finding highlights SUA

Area of Science:

  • Cardiology
  • Rheumatology
  • Vascular Biology

Background:

  • Rheumatoid arthritis (RA) significantly increases cardiovascular disease (CVD) risk.
  • Non-traditional cardiovascular risk factors, including serum uric acid (SUA), contribute to CVD in RA.
  • Subclinical atherosclerosis, measured by carotid intima-media thickness (cIMT), is a key indicator of cardiovascular risk.

Purpose of the Study:

  • To investigate the role of SUA as a cardiovascular risk factor in RA patients.
  • To correlate SUA levels with traditional cardiovascular risk factors and inflammation markers.
  • To determine the association between SUA and subclinical atherosclerosis (cIMT) in RA.

Main Methods:

  • Cross-sectional study of 53 RA patients without clinically evident CV or renal disease.
  • Assessment of cIMT using ultrasound (US).
  • Measurement of SUA, traditional cardiovascular risk factors, and inflammatory markers; correlation analysis performed.

Main Results:

  • Univariate analysis revealed positive correlations between cIMT and age, age at RA onset/diagnosis, smoking, blood pressure, and SUA.
  • Rheumatoid factor positivity and level were associated with increased cIMT.
  • Multivariate analysis confirmed SUA as a significant independent predictor of cIMT, along with age, LDL, and triglycerides.

Conclusions:

  • Serum uric acid (SUA) is identified as a significant cardiovascular risk factor in rheumatoid arthritis (RA).
  • Elevated SUA levels are associated with subclinical atherosclerosis (increased cIMT) in RA patients.
  • SUA should be considered in cardiovascular risk assessment and management strategies for RA patients.

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
516
Rheumatic Heart Disease I: Introduction01:23

Rheumatic Heart Disease I: Introduction

Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
647
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
1.3K
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
16.0K
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
776
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
420